Compare McKesson Corporation (MCK) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? McKesson Corporation trades at $983.95 (market cap $112.15B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.78 (market cap $6.35B). The key difference: McKesson Corporation is far larger — about 17.7× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (9.8%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| MCK | OWL | |
|---|---|---|
Market Cap | $112.15B | $6.35B |
Volume | 743,618 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $995.69 | $17.17 |
52-Week Low | $725.17 | $8.23 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $118.68B | $10.53B |
Dividend Yield | 0.39% | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
